BETHESDA, Md., June 16 (UPI) — U.S. medical investigators say an experimental vaccine for Marburg hemorrhagic fever continues to show promise in animal tests as an emergency treatment.
The research — overseen by a team from the National Institutes of Health and three other organizations with expertise in viral hemorrhagic fevers — focuses on a vaccine developed as an emergency treatment for accidental exposures to the virus that causes the disease. There is no approved treatment for Marburg infection, which has a high fatality rate.
In a study involving rhesus macaques, 5 of 6 monkeys survived a lethal dose of Marburg virus when treated 24 hours after infection, and 2 of 6 survived when treated 48 hours after infection. But researchers said since rhesus macaques typically succumb to Marburg infection faster than humans, the post-exposure treatment window might be extended even further in humans.
The findings are detailed in the early online edition of the journal Emerging Infectious Diseases.
Copyright 2010 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI’s prior written consent.